logo
  Join        Login             Stock Quote

Seven Bull Stocks In Healthcare Sector

 February 17, 2011 01:56 PM
 


At the end of February 16,2011,132 stocks touched new 52 week highs and 19 stocks touched new 52 week lows on NASDAQ (compared to 61 to 13 yesterday). Figures for AMEX stood at 12 to 1 (10 to 1), while figures for NYSE were more optimistic with 207 to 10 (82 to 7).

Healthcare includes companies that operate in Biotechnology & Drugs, Healthcare Facilities, Major Drugs, and Medical Equipment & Supplies industries.

Picks from NASDAQ 52 week high

Threshold Pharmaceuticals, Inc. (NASDAQ:THLD), Syneron Medical Ltd. (NASDAQ:ELOS), Shire Plc. (ADR) (NASDAQ:SHPGY), Patterson Companies, Inc. (NASDAQ:PDCO), MWI Veterinary Supply, Inc. (NASDAQ:MWIV), Henry Schein, Inc. (NASDAQ:HSIC), Genzyme Corporation (NASDAQ:GENZ), AtriCure Inc. (NASDAQ:ATRC), and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

Picks from AMEX 52 week high

[Related -Homebuilders Surprise To The Downside]

Metropolitan Health Networks, Inc. (AMEX:MDF)

Picks from NYSE 52 week high

HEALTHSOUTH Corp. (NYSE:HLS)

Symbol

Sub sector

Y Close ($)

52 week high ($)

1 Y TP($)

C-1YTP%

THLD

Biotechnology & Drugs

2.75

3.34

5.50

2.16

[Related -iShares NASDAQ Biotechnology Index (ETF) (IBB): 3 Biotechs Up 132% In 2013 With Huge Upside Potential]

ELOS

Medical Equipment and Supplies

14.10

14.45

15.00

0.55

SHPGY

Biotechnology & Drugs

83.46

83.88

83.58

0.30

PDCO

Medical Equipment and Supplies

34.16

34.34

35.58

1.24

MWIV

Biotechnology & Drugs

71.60

72.27

69.83

2.44

HSIC

Medical Equipment and Supplies

68.76

69.12

66.00

3.12

GENZ

Biotechnology & Drugs

75.10

73.23

72.50

0.73

ATRC

Medical Equipment and Supplies

11.49

11.79

12.50

0.71

ALXN

Biotechnology and Drugs

92.41

92.81

94.39

1.58

MDF

Healthcare Facilities

5.00

5.02

5.28

0.26

HLS

Healthcare Facilities

24.39

24.57

25.81

1.24

Y Close – yesterday's closing price

1 Y TP – one year target price

C-1YTP% - one year target price change percentage over Y Close

Since, out of the 11 healthcare companies that set new 52 week highs, the target price for 4 companies are lower than yesterday' closing prices, so we are left with our seven picks from the sector.

Threshold Pharmaceuticals, Inc.

Threshold's product line includes TH-302, a product candidate in Phase I and Phase I/II for the potential treatment of patients with cancer; and 2DG, a product candidate for the potential treatment of patients with cancer and has been evaluated in a Phase I clinical trial alone and in combination with docetaxel as a combination therapy.

In the last five trading sessions, the 50-day MA has climbed 2.54% while the 200-day MA has remained constant. In the past 52 weeks, shares of Threshold Pharmaceuticals have traded between a low of $0.98 and a high of $2.25 and are now at $2.09, which is 113% above that low price.

Syneron Medical Ltd.

The company develops products based on its proprietary ELOS technology, which combines conducted radiofrequency energy, an electrical energy; and light or laser-based energy, an optical energy. Its products target a range of non-invasive aesthetic medical procedures, including hair removal, wrinkle reduction, and rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, acne treatment, treatment of leg veins, treatment for the temporary reduction in the appearance of cellulite and thigh circumference, ablation and resurfacing of the skin, and invasive products for laser-assisted lipolysis, as well as develops dental laser devices.

The company ended 2010 with its highest quarterly revenue, and first profitable quarter of the year, demonstrating its ability to grow and leverage the combination of Syneron and Candela. Total revenue for the fourth quarter was up 15% year-over-year and up 20% over the third quarter. The year-over-year revenue increase was driven by 20% international growth and 6% growth in North America.

Patterson Companies, Inc.

Patterson Companies (formerly Patterson Dental), one of two large distributors of dental products in North America, is a full-service supplier to dentists, dental laboratories, institutions, physicians, and other health care professionals. It has a 35% share of a $6 billion market.

Through the July 2001 acquisition of J.A. Webster, PDCO became the second largest U.S. distributor of companion-pet veterinary supplies. Also, through the August 2003 acquisition of AbilityOne Products Corp. (now Patterson Medical), PDCO became the largest distributor of non-wheelchair assistive products for patient rehabilitation in the U.S. and the U.K.

In the last four quarters ended October 2010, the company's reported EPS either met or exceeded analysts' consensus estimates. The company said it will release operating results for the third quarter of fiscal 2011 on Thursday, February 24, 2011. Fourth quarter EPS is expected to be in the range of $0.5 and $0.53.

AtriCure Inc.

The Company has three primary product lines. Its primary product line, which accounts for a majority of its revenues, is Isolator Synergy bipolar ablation clamp system (Isolator system) and related radiofrequency ablation devices. It also offers a cryoablation product line, which features reusable and disposable cryoablation devices.

Fourth quarter 2011 revenue was $16.4 million, which represents AtriCure's highest quarterly revenue in constant currency revenue growth of 20%. Domestic revenue was $13.1 million, up 21% and international revenue was $3.3 million, up 18% on a constant currency basis. In terms of profitability and operating leverage ATRC reported positive quarterly net income for the first time and fourth quarter adjusted EBITDA was a record $1 million. These results reflect its continued focus on cost control and high gross margins while investing in innovation, sales force expansion and obtaining regulatory approvals.

Alexion Pharmaceuticals, Inc

The company's marketed product Soliris (eculizumab) is the first therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria, or PNH. During 2009, Soliris launched in Europe's five largest markets, including the U.K. in the second quarter of 2009. Soliris was approved in Japan in April 2010, and launched early in the third quarter of 2010, earlier than initially projected.

Metropolitan Health Networks, Inc

The Company provides and arranges for medical care to Medicare Advantage beneficiaries in the State of Florida who have enrolled in health plans operated by Humana, Inc. (Humana), or subsidiaries of Humana. Humana is one of the participants in the Medicare Advantage program in the United States.

HEALTHSOUTH Corp.

The Company operates 93 inpatient rehabilitation hospitals, six freestanding long-term acute care hospitals (LTCHs), 40 outpatient rehabilitation satellites (operated by its hospitals), and 25 licensed, hospital-based home health agencies.

iOnTheMarket Premium
Advertisement

Advertisement


Comments Closed


rss feed

Latest Stories

article imageChipotle Mexican Grill, Inc. (CMG) Q2 Earnings Preview: Will Higher Traffic Offset Higher Costs the Key

Chipotle Mexican Grill, Inc. (NYSE:CMG) will host a conference call to discuss second quarter 2014 read on...

article imageNetflix, Inc. (NFLX) Q2 Earnings Preview: The Ruby Month for a Reason

Netflix, Inc. (NASDAQ:NFLX) will post its second-quarter 2014 financial results and business outlook on its read on...

article imageLadenburg Thalmann Financial Services (NYSEMKT:LTS): Heavy, Durable Insider Buying

Ahh, but any worries over price levels didn’t stop multiple insiders at Ladenburg Thalmann Financial read on...

article imageInternational Business Machines Corp. (IBM) Q2 Earnings Preview: Small Beat and Pop

International Business Machines Corp. (NYSE:IBM) will host a conference call Wednesday, Jul. 16, 2014 at read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.